Evidence map›Paper›PMID 41193953›Full record

ReviewCellular & molecular biology letters2025

The ISGylation tapestry in cancer: weaving phenotypic plasticity through multidimensional regulatory looms.

Ruicheng Wu, Fanglin Shao, Siang Boon Koh, Uzoamaka Adaobi Okoli, Dengxiong Li, Jie Wang, Zhouting Tuo, Rong Zhang, Dilinaer Wusiman, Umber Cheema and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cellular & molecular biology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ruicheng Wu *Urology & Nephrology Center, Department of Urology, Affiliated People's Hospital, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Fanglin Shao *Department of Rehabilitation, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China.
Siang Boon Koh *Faculty of Health and Life Sciences, University of Bristol, Bristol, BS8 1TD, UK.
Uzoamaka Adaobi Okoli *Division of Surgery & Interventional Science, University College London, London, W1W 7TS, UK.
Dengxiong LiDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Jie WangDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Zhouting TuoDepartment of Urological Surgery, Daping Hospital, Army Medical Center of PLA, Army Medical University, Chongqing, China.
Rong ZhangClinical Medicine Research Institute, Zhejiang Provincial People's Hospital of Hangzhou Medical College, Hangzhou, China.
Dilinaer WusimanDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, 47907, USA.
Umber CheemaDivision of Surgery & Interventional Science, University College London, London, W1W 7TS, UK. u.cheema@ucl.ac.uk.
Depei KongDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. kongdepei@wchscu.cn.
Dechao FengUrology & Nephrology Center, Department of Urology, Affiliated People's Hospital, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China. dechao.feng@ucl.ac.uk.ORCID http://orcid.org/0009-0003-8587-6959

Funding

National Natural Science Foundation of China 82303151
6 · The paper itself

Abstract

Post-translational modification is an important mechanism for regulating protein function and cell signaling networks. Among these modifications, ISGylation is a ubiquitin-like modification regulated by ISG15. In this review, we explore the role of ISGylation in a variety of related phenotypes in the tumor context, including apoptosis regulation, autophagy regulation, immune escape, metabolic reprogramming, cancer stem cell maintenance, and DNA damage repair. ISGylation plays a dual role in apoptosis, promoting either pro-survival or pro-death pathways depending on contexts. It also regulates autophagy by promoting tumor adaptation or by regulating immune responses. Moreover, ISGylation contributes to the immune escape mechanism by regulating the stability of PD-L1 and immune cell infiltration. In addition, ISGylation is involved in metabolic reprogramming, supporting tumor growth and therapeutic resistance by regulating key metabolic pathways. It also plays a key role in maintaining the properties of cancer stem cells by stabilizing essential metabolic and signaling proteins. In sum, this review examines the functions and mechanisms of ISG15 and ISGylation in various tumor-associated phenotypes, enhancing our understanding of their role in tumorigenesis and disease progression.

Indexed as

CytokinesNeoplasmsProtein Processing, Post-TranslationalUbiquitinsAnimalsApoptosisAutophagyHumansNeoplastic Stem CellsPhenotypeSignal TransductionCytokinesISG15 protein, humanUbiquitinsDrug resistanceImmune evasionISGylationPost-translational modificationTumor microenvironment

Identifiers

PMID41193953
PMCPMC12590619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.